Rifaximin (drug)

DRUG6 trials

Sponsors

Weill Medical College of Cornell University, Xiuli Zuo, Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji, Mahidol University, Fayoum University Hospital

Conditions

BloatingConstipationFunctional Bowel DisorderHepatic EncephalopathyHepatitis CIBSIrritable Bowel SyndromeIrritable Bowel Syndrome (IBS)

Phase 1

SIMBA in Irritable Bowel Syndrome (IBS)

Not yet recruitingNCT07882953

University of CalgaryIrritable Bowel Syndrome (IBS), Microbiome

Start: 2026-11-01End: 2028-09-01Target: 180Updated: 2026-10-20

Phase 2

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Weill Medical College of Cornell UniversityHepatic Encephalopathy, Hepatitis C, Liver Cirrhosis

Start: 2005-12-31End: 2012-12-31Target: 50Updated: 2010-11-05

Phase 3

Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders

Not yet recruitingNCT07522255

Mahidol UniversityBloating, Constipation, Functional Bowel Disorder +4

Start: 2026-12-01End: 2028-12-01Target: 78Updated: 2026-10-27

Phase 4

Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial

Not yet recruitingNCT07426705

Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i AdministracjiIBS, Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Start: 2026-02-15End: 2027-07-15Target: 100Updated: 2026-02-23

Effect of Rifaximin on Thrombocytopenia in Patients With HCV-Related Liver Cirrhosis

CompletedNCT07791940

Fayoum University HospitalThrombocytopenia Related to Chronic Liver Disease

Start: 2015-10-19End: 2017-12-30Updated: 2026-09-23

Unknown Phase

Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.

RecruitingNCT06772064

Start: 2025-04-15End: 2025-12-01Target: 115Updated: 2025-05-16